px-3 px-3 px-3 (also known as app-chminaca) is an indazole-based synthetic cannabinoid. it is a potent agonist of the cb1 receptor with a binding affinity of ki = 47.6 nm and was originally developed by pfizer in 2009 as an analgesic medication. px-3legal statuslegal status ca: schedule ii de: npsg (industrial and scientific use only) uk: class b illegal in sweden identifiers iupac name n--1-(cyclohexylmethyl)indazole-3-carboxamide cas number1185887-14-2pubchem cid44206137chemspider48063640unii3877t06h05comptox dashboard (epa)dtxsid201009998 chemical and physical dataformulac24h28n4o2molar mass404.514 g·mol−13d model (jsmol)interactive image smiles nc(=o)(cc1ccccc1)nc(=o)c2nn(cc3ccccc3)c4ccccc24 inchi inchi=1s/c24h28n4o2/c25-23(29)20(15-17-9-3-1-4-10-17)26-24(30)22-19-13-7-8-14-21(19)28(27-22)16-18-11-5-2-6-12-18/h1,3-4,7-10,13-14,18,20h,2,5-6,11-12,15-16h2,(h2,25,29)(h,26,30)/t20-/m0/s1key:dmhwdsgurmxmge-fqevstjzsa-n the acronym 'app' signifies the 'amino', 'phenyl' and 'propanone' elements of the structure. three related compounds, px-1 (5f-app-pica, srf-30), px-2 (5f-app-pinaca, fu-px) and app-fubinaca were reported by the emcdda in late 2014. legality sweden's public health agency suggested to classify app-chminaca as hazardous substance on june 1, 2015.